Purpose

Aim:

  1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.
  2. To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.

Condition Intervention
Non-Alcoholic Fatty Liver Disease (NAFLD)
 Procedure: Ultrasound to demonstrate existence of fatty liver

MedlinePlus related topics:   Liver Diseases  

U.S. FDA Resources

Study Type:   Observational
Study Design:   Screening, Longitudinal, Convenience Sample, Prospective Study

Further study details as provided by Shaare Zedek Medical Center:

Study Start Date:   September 2006
Estimated Study Completion Date:   September 2009

Detailed Description:

Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.

Serum samples will be frozen and kept for future ongoing research.

  Eligibility
Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Cardiology patient
  • Age above 18

Exclusion Criteria:

  • Age below 18
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00375349

Contacts
Contact: Michal Mates, MD     0544727635     Mates@013.net    
Contact: Ornit Cohen Biton, MA     0507867234     bionet@017.net.il    

Locations
Israel
Shaare Zedek Medical Center     Not yet recruiting
      Jerusalem, Israel, 91031
      Contact: Michal Mates, MD     0544727635     Mates@013.net    
      Principal Investigator: Michal Mates, MD            
      Sub-Investigator: David Meerkin, MD            

Sponsors and Collaborators
Shaare Zedek Medical Center

Investigators
Principal Investigator:     Michal Mates, MD     Shaare Zedek Medical Center    
Contact: Michal Mates, MD     0544727635     Mates@013.net    
Contact: Ornit Cohen Biton, MA     0507867234     bionet@017.net.il    
Israel
Shaare Zedek Medical Center     Not yet recruiting
      Jerusalem, Israel, 91031
      Contact: Michal Mates, MD     0544727635     Mates@013.net    
      Principal Investigator: Michal Mates, MD            
      Sub-Investigator: David Meerkin, MD            
Shaare Zedek Medical Center
Principal Investigator:     Michal Mates, MD     Shaare Zedek Medical Center    
  More Information

Publications:
Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006 Jan;184(1):233-4. Epub 2005 Oct 5. No abstract available.
 

Study ID Numbers:   20173CTIL
First Received:   September 11, 2006
Last Updated:   September 11, 2006
ClinicalTrials.gov Identifier:   NCT00375349
Health Authority:   Israel: Ethics Commission

Keywords provided by Shaare Zedek Medical Center:
fatty liver  
statin  
non-alcoholic  

Study placed in the following topic categories:
Liver Diseases
Non-alcoholic steatohepatitis (NASH)
Fatty Liver

Additional relevant MeSH terms:
Fatty Liver
Digestive System Diseases

Source: National Library of Medicine (NLM) July 03, 2008

  


 
Browse All News Categories
  

 
News Archive
  
 
Get Affordable Health Benefits